Table 3

The univariate analyses of the association between patients prognosis and clinicopathological valiables
Clinicopathological valiables No 5-year disease-free survival rate (%) p Value 3 No 5-year local recurrence-free survival rate (%) p Value 3 No 5-year metastasis-free survival rate (%) p Value 3 No 5-year overall survival rate (%) p Value 3
Age (years)
≦49 23 60.9% 0.1603 25 90.0% 0.0621 32 58.9% 0.5899 32 81.8% 0.0517
≧50 32 30.5% 31 62.4% 40 46.1% 41 56.0%
Gender
Male 26 50.2% 0.5806 29 76.1% 0.6890 36 60.4% 0.4844 36 68.8% 0.7350
Female 29 35.4% 27 76.5% 36 44.8% 37 66.1%
Size (cm)
<5 14 66.1% 0.0616 13 82.5% 0.9879 17 43.5% 0.0159 17 83.3% 0.1327
≧5 41 34.5% 43 73.4% 55 79.5% 56 63.0%
Depth
Superficial 3 66.7% 0.8647 3 66.7% 0.6414 6 62.5% 0.6888 6 75.0% 0.7062
Deep 52 42.1% 53 76.9% 66 51.0% 67 66.7%
Location 1
Trunk 16 34.4% 0.2593 13 65.6% 0.3231 24 54.7% 0.8741 25 69.4% 0.7125
Extremity 37 48.9% 43 77.9% 46 52.7% 46 67.1%
Histological grading
Low grade 13 69.2% 0.1171 13 100% 0.1026 14 84.6% 0.0108 14 91.7% 0.0426
High grade 42 31.4% 43 67.2% 58 58.4% 59 60.5%
Soluble Cadherin 2
  Low 40 55.1% 0.0022 40 83.5% 0.0123 51 51.0% 0.0107 52 73.0% 0.0334
  High 15 0% 16 60.6% 21 34.9% 21 50.4%

1 two patients with multiple sarcoms were excluded.

2 Low means <1,500 ng/ml, and high means ≧1,500 ng/ml.

3 Log-rank test.

Niimi et al.

Niimi et al. BMC Cancer 2013 13:309   doi:10.1186/1471-2407-13-309

Open Data